CL2023001750A1 - Useful compounds for inhibiting nav1.8 voltage-gated sodium channels and treating diseases - Google Patents
Useful compounds for inhibiting nav1.8 voltage-gated sodium channels and treating diseasesInfo
- Publication number
- CL2023001750A1 CL2023001750A1 CL2023001750A CL2023001750A CL2023001750A1 CL 2023001750 A1 CL2023001750 A1 CL 2023001750A1 CL 2023001750 A CL2023001750 A CL 2023001750A CL 2023001750 A CL2023001750 A CL 2023001750A CL 2023001750 A1 CL2023001750 A1 CL 2023001750A1
- Authority
- CL
- Chile
- Prior art keywords
- voltage
- sodium channels
- inhibiting
- gated sodium
- treating diseases
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 4
- 108010056565 NAV1.8 Voltage-Gated Sodium Channel Proteins 0.000 title abstract 2
- 102000004194 NAV1.8 Voltage-Gated Sodium Channel Human genes 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 abstract 1
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se describen compuestos de la fórmula (I), en donde cada uno de los grupos variables es como se define en la memoria descriptiva. También se describen composiciones farmacéuticas que contienen un compuesto de la fórmula (I), y usos de los compuestos y composiciones farmacéuticas para inhibir los canales de sodio dependientes de voltaje de Nav1.8 y tratar enfermedades, trastornos y afecciones mediados por Nav1.8, tales como dolor y enfermedades, trastornos y afecciones asociados al dolor y enfermedades, trastornos y afecciones cardiovasculares.Compounds of formula (I) are described, where each of the variable groups is as defined in the specification. Also described are pharmaceutical compositions containing a compound of formula (I), and uses of the compounds and pharmaceutical compositions to inhibit Nav1.8 voltage-gated sodium channels and treat Nav1.8-mediated diseases, disorders and conditions, such as pain and diseases, disorders and conditions associated with pain and diseases, cardiovascular disorders and conditions.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063127341P | 2020-12-18 | 2020-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001750A1 true CL2023001750A1 (en) | 2024-01-19 |
Family
ID=79025144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001750A CL2023001750A1 (en) | 2020-12-18 | 2023-06-15 | Useful compounds for inhibiting nav1.8 voltage-gated sodium channels and treating diseases |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4262978A1 (en) |
| JP (1) | JP2024502231A (en) |
| KR (1) | KR20230121827A (en) |
| CN (1) | CN116710463A (en) |
| CA (1) | CA3202328A1 (en) |
| CL (1) | CL2023001750A1 (en) |
| CO (1) | CO2023008049A2 (en) |
| IL (1) | IL303795A (en) |
| MX (1) | MX2023007244A (en) |
| WO (1) | WO2022129283A1 (en) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA121379C2 (en) * | 2013-12-13 | 2020-05-25 | Вертекс Фармасьютикалз Інкорпорейтед | Prodrugs of pyridone amides useful as modulators of sodium channels |
-
2021
- 2021-12-16 EP EP21831047.2A patent/EP4262978A1/en active Pending
- 2021-12-16 IL IL303795A patent/IL303795A/en unknown
- 2021-12-16 JP JP2023536951A patent/JP2024502231A/en active Pending
- 2021-12-16 CN CN202180085151.XA patent/CN116710463A/en active Pending
- 2021-12-16 WO PCT/EP2021/086101 patent/WO2022129283A1/en active Application Filing
- 2021-12-16 CA CA3202328A patent/CA3202328A1/en active Pending
- 2021-12-16 KR KR1020237023878A patent/KR20230121827A/en unknown
- 2021-12-16 MX MX2023007244A patent/MX2023007244A/en unknown
-
2023
- 2023-06-15 CL CL2023001750A patent/CL2023001750A1/en unknown
- 2023-06-21 CO CONC2023/0008049A patent/CO2023008049A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024502231A (en) | 2024-01-18 |
| CA3202328A1 (en) | 2022-06-23 |
| MX2023007244A (en) | 2023-06-29 |
| KR20230121827A (en) | 2023-08-21 |
| CN116710463A (en) | 2023-09-05 |
| CO2023008049A2 (en) | 2023-06-30 |
| EP4262978A1 (en) | 2023-10-25 |
| AU2021403606A1 (en) | 2023-06-22 |
| WO2022129283A1 (en) | 2022-06-23 |
| IL303795A (en) | 2023-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022016377A2 (en) | Fused tricyclic kras inhibitors | |
| MA45223B1 (en) | New piperidinyl derivatives substituted by (hetero) aryl, their preparation process and pharmaceutical compositions containing them | |
| MA43639B1 (en) | New ammonium derivatives, process for their preparation and pharmaceutical compositions containing them | |
| ECSP24009853A (en) | TRICYCLIC COMPOUNDS AS KRAS INHIBITORS | |
| BR112021022758A2 (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, their compositions and methods of treatment therewith | |
| CO2022017903A2 (en) | Cyclobutyl Dihydroquinolinesulfonamide Compounds | |
| PE20211773A1 (en) | MONACILGLYCEROL LIPASE MODULATORS | |
| MA45222B1 (en) | Novel piperidinyl derivatives, process for their preparation and pharmaceutical compositions containing them | |
| ECSP066335A (en) | INDAZOL 3,5-DISPOSED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS TO INTERVENE IN OR INHIBIT THE CELL PROLIFERATION | |
| UY39264A (en) | CYCLOPROPYL DIHYDROQUINOLINSULFONAMIDE COMPOUNDS | |
| BR112021021477A2 (en) | Compound, pharmaceutical composition and method for treating a jak-mediated disease in an individual in need thereof | |
| CO2020011852A2 (en) | Oxadiazole transient potential receptor channel inhibitors | |
| BR112022020807A2 (en) | PYRAZOLE[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMASOME PATHWAY | |
| CO2022000749A2 (en) | Heterocyclic monoacylglycerol lipase (MAGL) inhibitors | |
| BR112023002957A2 (en) | COMPOUND, PHARMACEUTICAL COMPOSITION, AND, METHODS FOR TREATING NARCOLEPSY AND FOR TREATING HYPERSONIA IN A MAMMAL SUBJECT | |
| BR112023019496A2 (en) | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | |
| CO2024002075A2 (en) | n-acylhydrazonic compounds inhibitors of nav 1.7 and/or nav 1.8, their production processes, compositions, uses, treatment methods and kits | |
| CL2023001750A1 (en) | Useful compounds for inhibiting nav1.8 voltage-gated sodium channels and treating diseases | |
| UY38139A (en) | ANTI-REDNESS COMPOSITION AND METHODS TO TREAT SKIN REDNESS | |
| BR112022016131A2 (en) | COMPOUNDS FOR THE TREATMENT OF CORONA VIRUS INFECTION | |
| MX9200485A (en) | PROCESS FOR OBTAINING DERIVATIVES OF TETRA HIDRO PIRIDINA AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM. | |
| AR035587A1 (en) | A COMPOUND DERIVED FROM TRIPTAMINE AND ITS ANALOGS, AND A PHARMACEUTICAL COMPOSITION CONTAINING IT | |
| EA199800949A1 (en) | ANTIBACTERIAL COMPOUNDS OF CARBAPENEM CONTAINING THEIR PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATMENT | |
| FR2405067A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING MONOFUNCTIONAL DERIVATIVES OF PSORALENE FOR THE TREATMENT OF SKIN DISORDERS | |
| BE1002236A4 (en) | NOVEL BENZYLIDENE-CYCLANONES DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS ANTI-OXIDIZING AGENTS AND AS SOLAR FILTERS, COSMETIC AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |